<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4816555</article-id><article-id pub-id-type="pmid">27030970</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0152368</article-id><article-id pub-id-type="publisher-id">PONE-D-15-47869</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>Antibody-Producing Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>Antibody-Producing Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>Antibody-Producing Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Blood Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Hematology</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Spectrum Analysis Techniques</subject><subj-group><subject>Spectrophotometry</subject><subj-group><subject>Cytophotometry</subject><subj-group><subject>Flow Cytometry</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogenesis</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Proteinuria</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Proteinuria</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Blood Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>Lymphocytes</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>Lymphocytes</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>Lymphocytes</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>Lymphocytes</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System</subject><subj-group><subject>Immune Complex</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System</subject><subj-group><subject>Immune Complex</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Immunologic Techniques</subject><subj-group><subject>Immunoassays</subject><subj-group><subject>Enzyme-Linked Immunoassays</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>A Lower Proportion of Regulatory B Cells in Patients with Henoch–Schoenlein Purpura Nephritis </plain></SENT>
</text></SecTag></article-title><alt-title alt-title-type="running-head">Bregs in Henoch-Schoenlein Purpura Nephritis</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Hu</surname><given-names>Xintong</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Tai</surname><given-names>Jiandong</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Qu</surname><given-names>Zhihui</given-names></name><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Songchen</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Li</given-names></name><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Man</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Xiguang</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><name><surname>Jiang</surname><given-names>Yanfang</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Genetic Diagnosis Center, The First Hospital of Jilin University, Changchun, China</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Key Laboratory of Zoonoses Research, Ministry of Education, The First Hospital of Jilin University, Changchun, China</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou, China</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Department of Nephrology, the First Hospital of Jilin University, Changchun, China</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>van Zelm</surname><given-names>Menno C</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Monash University, AUSTRALIA</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><text><SENT sid="1" pm="."><plain>Competing Interests: The authors have declared that no competing interests exist. </plain></SENT>
</text></p></fn><fn fn-type="con" id="contrib001"><p><text><SENT sid="2" pm="."><plain>Conceived and designed the experiments: YJ XS XH. </plain></SENT>
<SENT sid="3" pm="."><plain>Performed the experiments: XH SZ JT YJ. </plain></SENT>
<SENT sid="4" pm="."><plain>Analyzed the data: SZ ZQ. </plain></SENT>
<SENT sid="5" pm="."><plain>Contributed reagents/materials/analysis tools: SZ LZ ML. </plain></SENT>
<SENT sid="6" pm="."><plain>Wrote the paper: YJ JT XH. </plain></SENT>
<SENT sid="7" pm="."><plain>Obtained Blood: ZQ LZ. </plain></SENT>
</text></p></fn><corresp id="cor001">* E-mail: <email>yanfangjiang@jlu.edu.cn</email> (YFJ); <email>xi-guangsun@hotmail.com</email>(XGS)</corresp></author-notes><pub-date pub-type="epub"><day>31</day><month>3</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>11</volume><issue>3</issue><elocation-id>e0152368</elocation-id><history><date date-type="received"><day>4</day><month>11</month><year>2015</year></date><date date-type="accepted"><day>13</day><month>3</month><year>2016</year></date></history><permissions><copyright-statement>© 2016 Hu et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Hu et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="pone.0152368.pdf"/><abstract><sec id="sec001"><title><text><SENT sid="8" pm="."><plain>Background </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="9" pm="."><plain>Henoch—Schoenlein purpura is the one of most common types of systemic vasculitis that involves impaired renal function and Henoch-Schoenlein purpura nephritis (HSPN). </plain></SENT>
<SENT sid="10" pm="."><plain>The diagnosis of this condition is largely based on immunohistologic detection of immunoglobulin A1-containing immune complex in the glomerular deposits of mesangium. </plain></SENT>
<SENT sid="11" pm="."><plain>Despite clinical advances, the etiopathogenesis of HSPN is still largely unknown. </plain></SENT>
</text></SecTag></p></sec><sec id="sec002"><title><text><SENT sid="12" pm="."><plain>Methods </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="13" pm="."><plain>In this study, we enrolled 25 newly diagnosed HSPN patients and 14 healthy controls. </plain></SENT>
<SENT sid="14" pm="."><plain>Then, fractions of B cell subtypes were determined in venous blood using flow cytometry. </plain></SENT>
<SENT sid="15" pm="."><plain>The serum interleukin (IL)-10 concentration was determined by enzyme-linked immunosorbent assay. </plain></SENT>
</text></SecTag></p></sec><sec id="sec003"><title><text><SENT sid="16" pm="."><plain>Results </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="17" pm="."><plain>Compared to those in healthy controls, the numbers of CD38+CD19+, CD86+CD19+, CD38+CD86+CD19+, and CD95+CD19+ B cells per microliter of blood were significantly higher in HSPN patients. </plain></SENT>
<SENT sid="18" pm="."><plain>In contrast, the numbers of CD5+CD19+, IL-10+CD19+, CD5+CD1d+CD19+, and IL-10+CD5+CD1d+CD19+ B cells per microliter of blood and the serum IL-10 concentration were significantly lower in HSPN patients. </plain></SENT>
<SENT sid="19" pm="."><plain>Following treatment, the numbers of CD38+CD19+ and CD86+CD19+ B cells per microliter of blood were significantly reduced in HSPN patients. </plain></SENT>
<SENT sid="20" pm="."><plain>However, the numbers of CD5+CD1d+CD19+, CD5+CD1d+IL-10+CD19+, and IL-10+CD19+ B cells per microliter of blood and the serum IL-10 concentration were significantly increased in HSPN patients following treatment. </plain></SENT>
<SENT sid="21" pm="."><plain>The estimated glomerular filtration rate (eGFR) was negatively correlated with the number of CD38+CD19+ B cells but positively correlated with the numbers of IL-10+CD19+, CD1d+CD5+CD19+, and IL-10+CD1d+CD5+CD19+B cells per microliter of blood and the serum IL-10 concentration. </plain></SENT>
<SENT sid="22" pm="."><plain>The 24-h urinary protein concentration was positively correlated with the number of CD38+CD19+B cells but negatively correlated with the numbers of IL-10+CD19+, CD1d+CD5+CD19+, and IL-10+CD1d+CD5+CD19+B cells per microliter of blood and the serum IL-10 concentration. </plain></SENT>
</text></SecTag></p></sec><sec id="sec004"><title><text><SENT sid="23" pm="."><plain>Conclusion </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="24" pm="."><plain>Our results suggest that CD38+CD19+ and CD1d+CD5+CD19+ B cells (Bregs) contribute to the pathogenesis of HSPN. </plain></SENT>
</text></SecTag></p></sec></abstract><funding-group><funding-statement>The authors received no specific funding for this work.</funding-statement></funding-group><counts><fig-count count="6"/><table-count count="2"/><page-count count="15"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its Supporting Information files.</p></notes></front><body><SecTag type="INTRO"><sec sec-type="intro" id="sec005"><title><text><SENT sid="25" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="26" pm="."><plain>Henoch—Schoenlein purpura (HSP) is a systemic vasculitis that affects small vessels. </plain></SENT>
<SENT sid="27" pm="."><plain>In this condition, patients develop perivascular inflammatory cell infiltrates. </plain></SENT>
<SENT sid="28" pm="."><plain>It is an immunoglobulin A-related immune complex-mediated disease that adversely affects the skin, joints, and gastrointestinal system, especially the kidney [1,2]. </plain></SENT>
<SENT sid="29" pm="."><plain>In recent studies, it has been reported that glomerular damage occurs in patients with HSPN, and such damage might be due to the deposition of mesangial Gd-IgA1-containing immune complex, which acts as a potential mediator via mesangial receptors. </plain></SENT>
<SENT sid="30" pm="."><plain>Subsequently, complement-mediated stimulation of mesangial cells occurs, leading to their proliferation. </plain></SENT>
<SENT sid="31" pm="."><plain>Moreover, cytokine secretion is also stimulated under such circumstances [3]. </plain></SENT>
<SENT sid="32" pm="."><plain>However, IgA deposition recurs in some patients even after they undergo renal transplantation [4,5]. </plain></SENT>
<SENT sid="33" pm="."><plain>In such patients, we detect mild forms of IgA nephropathy (IgAN), because there is deposition of immune complex and nephritic changes [6]. </plain></SENT>
<SENT sid="34" pm="."><plain>As a result, we usually detect an extrarenal source of antigen and an antibody immune complex in these patients. </plain></SENT>
<SENT sid="35" pm="."><plain>Furthermore, B cells are divided into different subsets depending on the presence of surface molecules. </plain></SENT>
<SENT sid="36" pm="."><plain>In the peripheral blood, naive and memory B cells express different amounts of CD27 [7]. </plain></SENT>
<SENT sid="37" pm="."><plain>This indicates that activated CD27+ B cells can establish memory responses [8]. </plain></SENT>
<SENT sid="38" pm="."><plain>Activated B cells can differentiate into CD38+ plasma cells that secrete antibodies [9,10] and cytokines, which enhance the expression of co-stimulation molecules, especially CD86 (which is an established marker of B-cell activation) and CD95 [11,12]. </plain></SENT>
<SENT sid="39" pm="."><plain>The CD95 receptor is considered to be a key regulator in the activation of germ cell apoptosis [13]. </plain></SENT>
<SENT sid="40" pm="."><plain>These different subtypes of B cells are known to collaborate and control the responses of the human immune system; however, very little information is available regarding the mechanisms governing the onset of HSPN in patients. </plain></SENT>
</text></p><p><text><SENT sid="41" pm="."><plain>B cells are primary positive regulators that have the ability to produce Ag-specific Ig and multiple cytokines. </plain></SENT>
<SENT sid="42" pm="."><plain>However, regulatory B cells (Bregs), which are a subset of B cells, have been found to have negative regulatory function [14]. </plain></SENT>
<SENT sid="43" pm="."><plain>Presently, in murine models with autoimmune disease, scientists have established that Breg subsets have immunosuppressive activity. </plain></SENT>
<SENT sid="44" pm="."><plain>This includes B cell subsets that express interleukin (IL)-10 and transforming growth factor (TGF)-β, which can facilitate the recruitment and expansion of regulatory T cells (Tregs) [15–22]. </plain></SENT>
<SENT sid="45" pm="."><plain>In preliminary studies, scientists have proved that Bregs play a critical regulatory role in experimental autoimmune encephalomyelitis (EAE). </plain></SENT>
<SENT sid="46" pm="."><plain>Moreover, they also suppress intestinal inflammation in murine models [23,24]. </plain></SENT>
<SENT sid="47" pm="."><plain>In previous studies, we have proved that activated B and T follicular helper (TFH) cells can contribute to the pathogenesis of minimal change disease (MCD) and hepatitis B virus-associated membranous nephropathy (HBV-MN) [25,26]. </plain></SENT>
<SENT sid="48" pm="."><plain>In addition, we have found that several CD19+ B cell subtypes and IL-10+ Bregs are differentially expressed in IgA-nephritis patients [27]. </plain></SENT>
<SENT sid="49" pm="."><plain>Moreover, previous studies have also reported that IL-10–producing B cells are actively involved in regulating Th1 and Th17 responses in a model of collagen-induced arthritis [28]. </plain></SENT>
<SENT sid="50" pm="."><plain>In these models, B cells that produce IL-10 play a critical role, and a new IL-10+ B cell subset was recently characterized by a CD1dhiCD5+CD19+ phenotype [14,29–31]. </plain></SENT>
<SENT sid="51" pm="."><plain>Presently, very little information is available about the association between Bregs and HSPN. </plain></SENT>
</text></p><p><text><SENT sid="52" pm="."><plain>In this study, we evaluated the numbers (per microliter of blood) of various B cell subtypes and IL-10–producing B cells that were isolated from the peripheral blood of patients with HSPN and healthy controls (HCs). </plain></SENT>
<SENT sid="53" pm="."><plain>Thus, we investigated the potential association between the differential expression of B cell subtypes before treatment and the dynamic changes in these B cell subtypes after treatment. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="materials|methods" id="sec006"><title><text><SENT sid="54" pm="."><plain>Materials and Methods </plain></SENT>
</text></title><sec id="sec007"><title><text><SENT sid="55" pm="."><plain>Patients and controls </plain></SENT>
</text></title><p><text><SENT sid="56" pm="."><plain>A total of 25 patients with new onset HSPN (defined by a disease duration of &lt;2 months) were recruited through the inpatient service of the Department of Nephrology of the First Hospital of Jilin University from January 2015 to October 2015. </plain></SENT>
<SENT sid="57" pm="."><plain>We excluded patients with any of the following conditions: IgA-nephritis, lupus nephritis, other primary glomerulonephritides, neoplastic disease, active peptic ulcer, diabetes mellitus, and viral hepatitis. </plain></SENT>
<SENT sid="58" pm="."><plain>In the control group, we included 14 HCs who matched the experimental subjects in terms of age, gender and ethnicity. </plain></SENT>
<SENT sid="59" pm="."><plain>None of the subjects in the control group had a history of any kind of chronic inflammatory disease. </plain></SENT>
<SENT sid="60" pm="."><plain>All the included patients fulfilled the EULAR/PRINTO/PRES (European League against Rheumatism/Paediatric Rheumatology International Trials Organisation/Paediatric Rheumatology European Society) criteria for HSP, which is defined as purpura plus; the included patients experienced at least one of the following symptoms: 1) abdominal pain; 2) typical leukocytoclastic vasculitis or proliferative glomerulonephritis with IgA deposits, as confirmed by histopathological examination; 3) arthritis or arthralgia; and 4) renal involvement [32]. </plain></SENT>
<SENT sid="61" pm="."><plain>HSPN patients develop either a nephritic or a nephrotic syndrome. </plain></SENT>
<SENT sid="62" pm="."><plain>Nephritic syndrome is defined as hematuria with at least one of the following symptoms: renal insufficiency, hypertension, and oliguria. </plain></SENT>
<SENT sid="63" pm="."><plain>Here, nephrotic syndrome was defined by proteinuria &gt;400 mg/day or hematuria. </plain></SENT>
<SENT sid="64" pm="."><plain>In some studies, it has been reported that patients with nephrotic syndrome also develop edema and have serum albumin levels &lt;2.5 g/dl [33,34]. </plain></SENT>
<SENT sid="65" pm="."><plain>All the participants signed a written informed consent form, and this study was approved by the Ethical Committee of the First Hospital of Jilin University. </plain></SENT>
<SENT sid="66" pm="."><plain>The demographic and clinical characteristics of participants are summarized in Table 1. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pone.0152368.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0152368.t001</object-id><label>Table 1</label><caption><title><text><SENT sid="67" pm="."><plain>Demographic and clinical characteristics of HSPN patients and HCs. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone.0152368.t001g" xlink:href="pone.0152368.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"><text><SENT sid="68" pm="."><plain>HSPN patients (n = 25) </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="69" pm="."><plain>HCs (n = 14) </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="70" pm="."><plain>Age, years </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="71" pm="."><plain>44(16–86) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="72" pm="."><plain>44(19–74) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="73" pm="."><plain>Female/male </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="74" pm="."><plain>12/10 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="75" pm="."><plain>8/6 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="76" pm="."><plain>Lymphocytes, 109/L </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="77" pm="."><plain>2.46(0.75–3.45) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="78" pm="."><plain>1.1 (0.4–1.74) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="79" pm="."><plain>Serum albumin, g/L </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="80" pm="."><plain>31.3(23–45.8) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="81" pm="."><plain>42.1(38.7–49) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="82" pm="."><plain>Serum uric acid, μmol/L </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="83" pm="."><plain>322(225–424) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="84" pm="."><plain>335(230–440) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="85" pm="."><plain>Triglycerides, mmol/L </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="86" pm="."><plain>3.02(0.7–4.27) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="87" pm="."><plain>1.15(0.35–1.63) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="88" pm="."><plain>Cholesterol, mmol/L </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="89" pm="."><plain>4.14(3.08–5.87) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="90" pm="."><plain>4.17(2.8–5.95) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="91" pm="."><plain>Urinary proteins, g/24 h </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="92" pm="."><plain>2.8(0.45–7.2) * </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="93" pm="."><plain>0.05(0–0.15) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="94" pm="."><plain>Urea nitrogen, mmol/L </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="95" pm="."><plain>4.84(2.93–7.71) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="96" pm="."><plain>5.05(3.65–6.74) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="97" pm="."><plain>eGFR, mL/min/1.73m2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="98" pm="."><plain>90.4(16.76–116) * </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="99" pm="."><plain>99 (90–109.14) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="100" pm="."><plain>Hematuria, n(%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="101" pm="."><plain>25(100%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="102" pm="."><plain>0(0%) </plain></SENT>
</text></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p><text><SENT sid="103" pm="."><plain>Data shown are median (range), real number of cases (n/n), and number of cases with percentage [n(%)]. </plain></SENT>
<SENT sid="104" pm="."><plain>eGFR: estimated glomerular filtration rate. </plain></SENT>
<SENT sid="105" pm="."><plain>Hematuria: defined as microscopic red blood cells &gt;3 rbc/hpf. </plain></SENT>
<SENT sid="106" pm="."><plain>Normal values: lymphocytes: 1.10–3.20 (109/L), serum albumin: 40.00–55.00 g/L, serum uric acid: 210–430 μmol/L, triglycerides: 0.28–1.6 mmol/L, cholesterol: 2.6–6.0 mmol/L, urinary protein: &lt;0.2 g/24 h, urea nitrogen: 3.2–7.0 mmol/L, eGFR: 80–120 ml/min. </plain></SENT>
</text></p></fn><fn id="t001fn002"><p><text><SENT sid="107" pm="."><plain>*P&lt;0.05 vs. HCs. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag></sec><sec id="sec008"><title><text><SENT sid="108" pm="."><plain>Treatment and follow-up </plain></SENT>
</text></title><p><text><SENT sid="109" pm="."><plain>Individual patients were treated orally with glucocorticoid prednisolone (PDN, Tianyao Pharmaceuticals, Tianjin China) in a 1 mg/kg/day dosage for the first 2 months. </plain></SENT>
<SENT sid="110" pm="."><plain>This dosage of steroids was gradually tapered, and a maintenance dose of 10 mg/day was prescribed to these patients for the next 6 months, or a combination of oral immunosuppressants (tacrolimus capsules, 1 mg/day) to relieve urinary proteinuria. </plain></SENT>
<SENT sid="111" pm="."><plain>In addition, some patients were at a higher risk of developing a hypercoagulable state, and they were treated with dipyridamole (25 mg/day, Yunpeng Pharmaceutical, Shanxi, China). </plain></SENT>
<SENT sid="112" pm="."><plain>The patients were followed up for 8–12 weeks. </plain></SENT>
<SENT sid="113" pm="."><plain>Eight patients had complete records, and the other 17 patients were censored on follow-up. </plain></SENT>
<SENT sid="114" pm="."><plain>Blood samples for measurement of clinical lab values, B-cell values and IL-10 concentrations were collected before and after the treatment from January 2015 to June 2015. </plain></SENT>
</text></p></sec><sec id="sec009"><title><text><SENT sid="115" pm="."><plain>Clinical examination </plain></SENT>
</text></title><p><text><SENT sid="116" pm="."><plain>Venous blood samples (10 ml) were obtained from each participant; the blood samples were collected in heparinized tubes. </plain></SENT>
<SENT sid="117" pm="."><plain>A small volume of blood was used for isolating peripheral blood mononuclear cells (PBMCs) using density-gradient centrifugation (Amersham Biosciences, Little Chalfont, UK). </plain></SENT>
<SENT sid="118" pm="."><plain>The remaining blood samples were centrifuged for preparing serum samples. </plain></SENT>
<SENT sid="119" pm="."><plain>We determined the concentrations of serum triglycerides, serum IgA cholesterol, albumin, uric acid, leukocytes and lymphocytes using ADVIA 1650 biochemical analyzer (Bayer, Pittsburg, PA, USA). </plain></SENT>
<SENT sid="120" pm="."><plain>Moreover, we collected 24-hour urine samples from individual subjects to examine urinary proteinuria and microscopic hematuria. </plain></SENT>
<SENT sid="121" pm="."><plain>In addition, we calculated the estimated glomerular fitration rate (eGFR) of individual participants using the revised eGFR formula [35]. </plain></SENT>
</text></p></sec><sec id="sec010"><title><text><SENT sid="122" pm="."><plain>Flow cytometric analysis </plain></SENT>
</text></title><p><text><SENT sid="123" pm="."><plain>Human PBMCs were stained at a cell density of 106/tube in duplicates. </plain></SENT>
<SENT sid="124" pm="."><plain>For the purpose of staining, we used PerCP-anti-CD19, PE-anti-CD38, APC-anti-CD86, or PerCP-anti-CD19, PE-anti-CD27, and APC-anti-CD95 or isotype-matched control IgG (BD Biosciences, San Jose, CA, USA). </plain></SENT>
<SENT sid="125" pm="."><plain>The staining was performed at room temperature, and the cells were protected from light for 30 minutes. </plain></SENT>
<SENT sid="126" pm="."><plain>After washing with phosphate-buffered saline (PBS), the cells were characterized using a FACS Calibur flow cytometer (BD Biosciences). </plain></SENT>
<SENT sid="127" pm="."><plain>Moreover, at least 30000 events per sample were analyzed using FlowJo software v7.6.2 (Ashland, OR, USA) [36]. </plain></SENT>
</text></p><p><text><SENT sid="128" pm="."><plain>To analyze the production of intracellular IL-10, we isolated PBMCs. </plain></SENT>
<SENT sid="129" pm="."><plain>The cells were then plated in 24-well plates (106cells/well) and stimulated with 50 ng/ml phorbol myristate acetate (PMA), 1.0 mg/ml ionomycin and 5.0 mg/ml lipopolysaccharide (LPS; Sigma—Aldrich, St. Louis, MO, USA) in complete RPMI-1640 medium for 2 h at 37°C in an atmosphere of 5% CO2. </plain></SENT>
<SENT sid="130" pm="."><plain>Then, brefeldin A (GolgiPlug; BD Biosciences) was added to each well, and the cells were incubated for another 4 h. </plain></SENT>
<SENT sid="131" pm="."><plain>Then, the cells were harvested and washed with PBS. </plain></SENT>
<SENT sid="132" pm="."><plain>Finally, these cells were stained in duplicate for 30 min using APC-anti-CD19, PE-anti-CD1d, and PerCP-anti-CD5 (BD Biosciences). </plain></SENT>
<SENT sid="133" pm="."><plain>After washing with PBS, the cells were permeabilized using a permeabilization solution (BD Biosciences). </plain></SENT>
<SENT sid="134" pm="."><plain>Thereafter, they were stained using FITC-anti-IL-10 (eBiosciences, San Diego, CA, USA). </plain></SENT>
<SENT sid="135" pm="."><plain>Finally, they were analyzed by flow cytometry using the aforementioned procedure. </plain></SENT>
<SENT sid="136" pm="."><plain>The details of the antibodies used for flow cytometry are provided in S1 Table. </plain></SENT>
</text></p></sec><sec id="sec011"><title><text><SENT sid="137" pm="."><plain>Enzyme-linked immunosorbent assay (ELISA) </plain></SENT>
</text></title><p><text><SENT sid="138" pm="."><plain>The serum concentration of IL-10 was determined by ELISA using a human IL-10 ELISA kit (Roche Diagnostics, Lewes, UK) according to the manufacturer’s instructions. </plain></SENT>
<SENT sid="139" pm="."><plain>At 1:4 dilutions, individual serums were briefly subjected to ELISA analysis. </plain></SENT>
<SENT sid="140" pm="."><plain>Thereafter, the serum concentrations of IL-10 were calculated in individual samples using the standard curve established for recombinant IL-10. </plain></SENT>
<SENT sid="141" pm="."><plain>The detection limit was 2.5 ng/L. </plain></SENT>
</text></p></sec><sec id="sec012"><title><text><SENT sid="142" pm="."><plain>Human cell isolation and culture </plain></SENT>
</text></title><p><text><SENT sid="143" pm="."><plain>We isolated B cells from PBMCs of five new onset HSPN patients via flow cytometry and staining with APC-anti-CD19 (BD Biosciences). </plain></SENT>
<SENT sid="144" pm="."><plain>The B cells were resuspended in D-10 (DMEM supplemented with 10% fetal calf serum, 100 U/mL penicillin, and 100 μg/mL streptomycin). </plain></SENT>
<SENT sid="145" pm="."><plain>Experiments were carried out in duplicate, and cell numbers were equal among the two groups for each patient: one group of D-10 with 1 μM prednisolone, and the other group without prednisolone. </plain></SENT>
<SENT sid="146" pm="."><plain>These samples were then distributed in wells of 24-well plates (Corning, Tewksbury, MA, USA) at 0.5–2×105 cells per well. </plain></SENT>
<SENT sid="147" pm="."><plain>After incubation at 37°C in a humidified atmosphere with 5% CO2 for 72 h, all cells in culture wells were harvested and stained with PE-anti-CD1d and PerCP-anti-CD5 (BD Biosciences) as described to determine the percentages of Bregs. </plain></SENT>
</text></p></sec><sec id="sec013"><title><text><SENT sid="148" pm="."><plain>Statistical analysis </plain></SENT>
</text></title><p><text><SENT sid="149" pm="."><plain>Data are expressed as means, medians, and ranges. </plain></SENT>
<SENT sid="150" pm="."><plain>The numbers of each type of cells tested were calculated according to the percentages of each type of cells multiplied by the lymphocyte count. </plain></SENT>
<SENT sid="151" pm="."><plain>The differences between the two groups were analyzed using Mann—Whitney U-test. </plain></SENT>
<SENT sid="152" pm="."><plain>The differences between pre-treatment and post-treatment patients were analyzed by the Wilcoxon test. </plain></SENT>
<SENT sid="153" pm="."><plain>The correlations were tested using Spearman’s rank correlation test. </plain></SENT>
<SENT sid="154" pm="."><plain>Statistical analysis was performed using SPSS 19.0 software (IBM, Armonk, NY, USA). </plain></SENT>
<SENT sid="155" pm="."><plain>Statistically significant cases were those in which the two-sided P-value &lt;0.5. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec sec-type="results" id="sec014"><title><text><SENT sid="156" pm="."><plain>Results </plain></SENT>
</text></title><sec id="sec015"><title><text><SENT sid="157" pm="."><plain>Patient characteristics </plain></SENT>
</text></title><p><text><SENT sid="158" pm="."><plain>There were no significant differences in the ages and gender ratio of HSPN patients and HCs. </plain></SENT>
<SENT sid="159" pm="."><plain>There were also no significant differences in the serum albumin concentration, serum uric acid concentration, urea nitrogen concentration, triglycerides, cholesterol, and lymphocyte counts of experimental cases and HCs. </plain></SENT>
<SENT sid="160" pm="."><plain>However, HSPN patients had significantly higher values of 24-h proteinuria compared to the control group. </plain></SENT>
<SENT sid="161" pm="."><plain>In addition, HSPN patients had a significantly lower eGFR compared to the HCs (Table 1). </plain></SENT>
<SENT sid="162" pm="."><plain>The clinical and basic immunological parameters of all individual patients and controls are described in S2 Table. </plain></SENT>
</text></p></sec><sec id="sec016"><title><text><SENT sid="163" pm="."><plain>Differential expression of B cell subsets </plain></SENT>
</text></title><p><text><SENT sid="164" pm="."><plain>In order to elucidate the potential role of different subsets of B cells involved in the pathogenesis of HSPN, we analyzed the numbers of different B cells subsets per microliter of blood of HSPN patients and HCs. </plain></SENT>
<SENT sid="165" pm="."><plain>The numbers of CD38+CD19+, CD86+CD19+, CD38+CD86+CD19+, and CD95+CD19+B cells per microliter of blood were significantly higher than those in HCs (all P&lt;0.05, Fig 1B–1F). </plain></SENT>
<SENT sid="166" pm="."><plain>However, there were no differences in the numbers of CD27+CD19+ and CD27+CD95+CD19+ B cells (data not shown). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone.0152368.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0152368.g001</object-id><label>Fig 1</label><caption><title><text><SENT sid="167" pm="."><plain>Flow cytometric analysis of the numbers of different subsets of B cells. </plain></SENT>
</text></title><p><text><SENT sid="168" pm="."><plain>PBMCs were collected from HSPN patients and healthy controls. </plain></SENT>
<SENT sid="169" pm="."><plain>Then, they were stained with PerCP-anti-CD19, PE-anti-CD38, APC-anti-CD86, or PerCP-anti-CD19, PE-anti-CD27, and APC-anti-CD95 (Biolegend, San Diego, CA, USA), or isotype-matched control IgG (Beckton Dickinson, San Jose, CA, USA). </plain></SENT>
<SENT sid="170" pm="."><plain>For further analysis of different subsets of B cells, the cells were gated initially on living lymphocytes and then on CD19+ B cells. </plain></SENT>
<SENT sid="171" pm="."><plain>(A) Flow cytometric analysis results. </plain></SENT>
<SENT sid="172" pm="."><plain>(B) The numbers of CD19+ B cells. </plain></SENT>
<SENT sid="173" pm="."><plain>(C) The numbers of CD38+CD19+ plasma cells. </plain></SENT>
<SENT sid="174" pm="."><plain>(D) The numbers of CD86+CD19+ B cells. </plain></SENT>
<SENT sid="175" pm="."><plain>(E) The numbers of CD38+CD86+CD19+ B cells. </plain></SENT>
<SENT sid="176" pm="."><plain>(F)The numbers of CD95+CD19+ B cells. </plain></SENT>
<SENT sid="177" pm="."><plain>Data are expressed as the means for individual subjects included in two separate experiments. </plain></SENT>
<SENT sid="178" pm="."><plain>(G) Mean fluorescence intensity of CD86 on B cells. </plain></SENT>
<SENT sid="179" pm="."><plain>(H) Mean fluorescence intensity of CD95 on B cells. </plain></SENT>
<SENT sid="180" pm="."><plain>(I) Mean fluorescence intensity of CD95 on CD27+ B cell subsets. </plain></SENT>
<SENT sid="181" pm="."><plain>(J) Mean fluorescence intensity of CD95 on CD27- B cell subsets. </plain></SENT>
<SENT sid="182" pm="."><plain>The horizontal lines represent the median values. </plain></SENT>
<SENT sid="183" pm="."><plain>Data were analyzed by Mann-Whitney U-test. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0152368.g001"/></fig></SecTag></sec><sec id="sec017"><title><text><SENT sid="184" pm="."><plain>The numbers of IL-10–producing B cells </plain></SENT>
</text></title><p><text><SENT sid="185" pm="."><plain>We analyzed the numbers of IL-10–producing B cells in patients with HSPN and HCs. </plain></SENT>
<SENT sid="186" pm="."><plain>The numbers of CD5+CD19+, CD1d+CD19+, IL-10+CD19+, CD1d+CD5+ CD19+ and IL-10+CD1d+CD5+CD19+ B cells in HSPN patients were significantly lower than those in HCs (all P&lt;0.05, Fig 2B–2E). </plain></SENT>
<SENT sid="187" pm="."><plain>Because Bregs play an immunoregulatory role that is primarily mediated via IL-10, we examined the serum concentrations of IL-10 in HSPN patients and HCs. </plain></SENT>
<SENT sid="188" pm="."><plain>We found that the serum IL-10 concentration was significantly lower in the HSPN patients (P&lt;0.001, Fig 2F). </plain></SENT>
<SENT sid="189" pm="."><plain>Our raw data can be found in S1 Fig. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone.0152368.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0152368.g002</object-id><label>Fig 2</label><caption><title><text><SENT sid="190" pm="."><plain>Flow cytometric analysis of Bregs isolated from PBMCs of HSPN patients and healthy controls. </plain></SENT>
</text></title><p><text><SENT sid="191" pm="."><plain>The cells were stained with anti-CD19, anti-CD5, anti-CD1d, and intracellular anti-IL-10 or isotype-matched IgG. </plain></SENT>
<SENT sid="192" pm="."><plain>The cells were characterized by flow cytometric analysis; living lymphocytes were gated initially, followed by gating on CD19+ B cells. </plain></SENT>
<SENT sid="193" pm="."><plain>Subsequently, we analyzed the numbers of CD5+CD19+, CD1d+CD5+CD19+, and IL-10+CD1d+CD5+CD19+ B cells among CD19+ B cells, and at least 30,000 events per sample were analyzed. </plain></SENT>
<SENT sid="194" pm="."><plain>(A) Flow cytometric analysis. </plain></SENT>
<SENT sid="195" pm="."><plain>(B) The numbers of CD5+CD19+ B cells. </plain></SENT>
<SENT sid="196" pm="."><plain>(C) The numbers of IL-10+CD19+ B cells. </plain></SENT>
<SENT sid="197" pm="."><plain>(D) The numbers of CD1d+CD5+CD19+ B cells. </plain></SENT>
<SENT sid="198" pm="."><plain>(E) The numbers of IL-10+CD1d+CD5+CD19+ B cells. </plain></SENT>
<SENT sid="199" pm="."><plain>(F) Serum concentrations of IL-10. </plain></SENT>
<SENT sid="200" pm="."><plain>Data are expressed as the means or concentrations for individual subjects that participated in two separate experiments. </plain></SENT>
<SENT sid="201" pm="."><plain>The horizontal lines represent the median values of each group. </plain></SENT>
<SENT sid="202" pm="."><plain>Data were analyzed by the Mann-Whitney U-test. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0152368.g002"/></fig></SecTag></sec><sec id="sec018"><title><text><SENT sid="203" pm="."><plain>Correlations between B cell subtypes, serum IL-10, and clinical parameters </plain></SENT>
</text></title><p><text><SENT sid="204" pm="."><plain>First, we analyzed the potential relationship between clinical parameters and different subsets of B cells. </plain></SENT>
<SENT sid="205" pm="."><plain>We found that eGFR was negatively correlated with the number of CD38+CD19+ B cells (Fig 3A, P = 0.0035, R = -0.6351), while 24-h proteinuria was positively correlated with the number of CD38+CD19+ B cells per microliter of blood (Fig 3F, R = 0.6684, P = 0.0018). </plain></SENT>
<SENT sid="206" pm="."><plain>Furthermore, we analyzed the potential relationships of serum IL-10, IL-10–producing B cells, and clinical parameters. </plain></SENT>
<SENT sid="207" pm="."><plain>In this case, we found that eGFR was positively correlated with the numbers of IL-10+CD19+ (Fig 3B, P = 0.0003, R = 0.7404), CD1d+CD5+CD19+ (Fig 3C, P = 0.0397, R = 0.4754), and IL-10+CD1d+CD5+CD19+ B cells (Fig 3D, P = 0.0477, R = 0.4596) per microliter of blood and the IL-10 serum concentration (Fig 3E, P = 0.0086, R = 0.5842). </plain></SENT>
<SENT sid="208" pm="."><plain>However, the 24-h proteinuria was negatively correlated with the numbers of IL-10+CD19+ (Fig 3G, P = 0.0077, R = –0.5912), CD1d+CD5+CD19+ (Fig 3H, P = 0.0154, R = –0.5467), and IL-10+CD1d+CD5+CD19+ B cells (Fig 3I, P = 0.0021, R = –0.6591) per microliter of blood and serum concentration of IL-10 (Fig 3J, P = 0.0232, R = –0.5175). </plain></SENT>
<SENT sid="209" pm="."><plain>In addition, there was no significant effect of age on the numbers of CD1d+CD5+CD19+ Bregs or IL-10+CD1d+CD5+CD19+ B cells (data not shown). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone.0152368.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0152368.g003</object-id><label>Fig 3</label><caption><title><text><SENT sid="210" pm="."><plain>Correlation analysis of clinico-pathological features of HSPN patients, based on the percentages of CD19+ B cell subtypes. </plain></SENT>
</text></title><p><text><SENT sid="211" pm="."><plain>(A) The eGFR was negatively correlated with the number of CD38+CD19+ B cells. </plain></SENT>
<SENT sid="212" pm="."><plain>(B) The eGFR was positively correlated with the numbers of IL-10+CD19+ B cells, (C) CD1d+CD5+CD19+ B cells (D), and IL-10+CD1d+CD5+CD19+ B cells (E) as well as the serum concentration of IL-10. </plain></SENT>
<SENT sid="213" pm="."><plain>(F) The 24-h urinary protein concentration was positively correlated with the number of CD38+CD19+ B cells. </plain></SENT>
<SENT sid="214" pm="."><plain>(G) The 24-h urinary protein concentration was negatively correlated with the numbers of IL-10+CD19+ B cells, (H) CD1d+CD5+CD19+ B cells, and (I) IL-10+CD1d+CD5+CD19+ B cells as well as the (J) serum concentration of IL-10. </plain></SENT>
<SENT sid="215" pm="."><plain>The potential correlations among the numbers of B cells of different subsets, Bregs, and the values of clinical parameters were analyzed by the Spearman correlation tests. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0152368.g003"/></fig></SecTag></sec><sec id="sec019"><title><text><SENT sid="216" pm="."><plain>Correlations between CD19+B cell subtypes and the proportion of IL-10–producing B cells </plain></SENT>
</text></title><p><text><SENT sid="217" pm="."><plain>The fraction of CD38+CD19+ B cells was negatively correlated with the serum IL-10 concentration (Fig 4A, P = 0.0047, R = –0.6193) and the number of IL-10+CD19+ B cells per microliter of blood (Fig 4B, P = 0.0244, R = –0.514). </plain></SENT>
<SENT sid="218" pm="."><plain>In addition, the number of CD86+CD19+ B cells was negatively correlated with the serum IL-10 concentration (Fig 4C, P = 0.0226, R = –0.5195) and the number of IL-10+CD19+ B cells (Fig 4D, P = 0.0145, R = –0.5509). </plain></SENT>
<SENT sid="219" pm="."><plain>In contrast, the numbers of CD1d+CD5+CD19+ (Fig 4E, P = 0.002, R = 0.6614) and IL-10+CD1d+CD5+CD19+ B cells (Fig 4F, P = 0.0245, R = 0.5273) per microliter of blood were positively correlated with the serum IL-10 concentration. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone.0152368.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0152368.g004</object-id><label>Fig 4</label><caption><title><text><SENT sid="220" pm="."><plain>Correlations among different subsets of B cells and the serum concentration of IL-10 in HSPN patients. </plain></SENT>
</text></title><p><text><SENT sid="221" pm="."><plain>Potential correlations among the numbers of B cells of different subsets and the serum concentration of IL-10 were analyzed by the Spearman correlation tests. </plain></SENT>
<SENT sid="222" pm="."><plain>Data are expressed as the means or concentrations for individual subjects that participated in two separate experiments. </plain></SENT>
<SENT sid="223" pm="."><plain>(A-B) The number of CD38+CD19+ B cells was negatively correlated with the serum IL-10 level and the percentage of IL-10+CD19+ B cells. </plain></SENT>
<SENT sid="224" pm="."><plain>(C-D) The number of CD86+CD19+ B cells was negatively correlated with the serum IL-10 level and the number of IL-10+CD19+ B cells. </plain></SENT>
<SENT sid="225" pm="."><plain>(E-F) The serum IL-10 level was positively correlated with the numbers of CD1d+CD5+CD19+ and IL-10+CD1d+CD5+CD19+ B cells. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0152368.g004"/></fig></SecTag></sec><sec id="sec020"><title><text><SENT sid="226" pm="."><plain>Clinical parameters, different subsets of B cells, and serum IL-10 concentration in HSPN patients following treatment </plain></SENT>
</text></title><p><text><SENT sid="227" pm="."><plain>In order to better understand the function of different subsets of B cells and serum IL-10 in the progression of HSPN, we assessed the values of clinical parameters, the numbers of B cells of different subsets, and the serum IL-10 concentrations in eight patients who reported for follow-up sessions within 8–12 weeks. </plain></SENT>
<SENT sid="228" pm="."><plain>We found that 24-h proteinuria had decreased significantly in these patients, whereas eGFR had increased (Table 2). </plain></SENT>
<SENT sid="229" pm="."><plain>In addition, the serum level of IL-10 had significantly increased as compared to the pre-treatment levels (Fig 5A, P = 0.002). </plain></SENT>
<SENT sid="230" pm="."><plain>Similarly, the numbers of IL-10+CD19+ (Fig 5D, P&lt;0.001), CD1d+CD5+CD19+ (Fig 5E, P&lt;0.001), and IL-10+CD1d+CD5+CD19+ B cells (Fig 5F, P = 0.001) had increased compared to pre-treatment values. </plain></SENT>
<SENT sid="231" pm="."><plain>Conversely, the numbers of CD38+CD19+ (Fig 5B, P = 0.001) and CD86+CD19+ B cells (Fig 5C, P&lt;0.001) had decreased compared to the pre-treatment values. </plain></SENT>
<SENT sid="232" pm="."><plain>Then, we analyzed the correlation between the number of CD38+CD19+ B cells and the serum IgA concentration in HSPN patients and found that the serum IgA concentration was positively correlated with the number of CD38+CD19+ B cells (Fig 6B, P = 0.0303, R = 0.4338). </plain></SENT>
<SENT sid="233" pm="."><plain>Moreover, the number of Bregs post-treatment was significantly higher than that pre-treatment (Fig 5G, P = 0.018) based on in vitro culture. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pone.0152368.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0152368.t002</object-id><label>Table 2</label><caption><title><text><SENT sid="234" pm="."><plain>The effect of treatment on the clinical parameters of HSPN patients during the follow-up period. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone.0152368.t002g" xlink:href="pone.0152368.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"><text><SENT sid="235" pm="."><plain>Before treatment </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="236" pm="."><plain>After treatment </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="237" pm="."><plain>Age, years </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="238" pm="."><plain>43(18–74) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="239" pm="."><plain>43(18–74) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="240" pm="."><plain>Female/male </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="241" pm="."><plain>3/5 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="242" pm="."><plain>3/5 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="243" pm="."><plain>Lymphocytes, 109/L </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="244" pm="."><plain>2.65(1.58–2.93) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="245" pm="."><plain>2.63(1.27–2.79) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="246" pm="."><plain>Serum albumin, g/L </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="247" pm="."><plain>30.2(25–39.5) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="248" pm="."><plain>33.2(25.5–40.7) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="249" pm="."><plain>Serum uric acid, μmol/L </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="250" pm="."><plain>321(281–398) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="251" pm="."><plain>312(267–380) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="252" pm="."><plain>Triglycerides, mmol/L </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="253" pm="."><plain>3.02(1.05–4.27) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="254" pm="."><plain>2.98(1.34–3.92) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="255" pm="."><plain>Cholesterol, mmol/L </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="256" pm="."><plain>4.34(3.16–5.87) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="257" pm="."><plain>4.02(2.94–5.35) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="258" pm="."><plain>Urinary proteins, g/24 h </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="259" pm="."><plain>3.6(2.38–7.2) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="260" pm="."><plain>2.55(1–5.62) * </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="261" pm="."><plain>Urea nitrogen, mmol/L </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="262" pm="."><plain>5.31(3.36–7.71) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="263" pm="."><plain>4.65(3.22–6.98) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="264" pm="."><plain>eGFR, mL/min/1.73m2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="265" pm="."><plain>88(16.76–102) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="266" pm="."><plain>91.2(26.89–108.6)* </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="267" pm="."><plain>Hematuria, n(%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="268" pm="."><plain>8(100%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="269" pm="."><plain>2(25%) </plain></SENT>
</text></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p><text><SENT sid="270" pm="."><plain>Data shown are median (range), real number of cases (n/n), and number of cases with percentage [n(%)]. </plain></SENT>
<SENT sid="271" pm="."><plain>eGFR: estimated glomerular filtration rate. </plain></SENT>
<SENT sid="272" pm="."><plain>Hematuria: defined as microscopic red blood cells &gt;3 rbc/hpf. </plain></SENT>
<SENT sid="273" pm="."><plain>Normal values: lymphocytes: 1.10–3.20 (109/L), serum albumin: 40.00–55.00 g/L, serum uric acid: 210–430 μmol/L, triglycerides: 0.28–1.6 mmol/L, cholesterol: 2.6–6.0 mmol/L, urinary proteins: &lt;0.2 g/24 h, urea nitrogen: 3.2–7.0 mmol/L, eGFR: 80–120 ml/min. </plain></SENT>
</text></p></fn><fn id="t002fn002"><p><text><SENT sid="274" pm="."><plain>*P&lt;0.05 vs. the values before treatment. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="FIG"><fig id="pone.0152368.g005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0152368.g005</object-id><label>Fig 5</label><caption><title><text><SENT sid="275" pm="."><plain>The change in the frequency of B cell subtypes and the serum concentration of IL-10 in HSPN patients following treatment. </plain></SENT>
</text></title><p><text><SENT sid="276" pm="."><plain>Differences in patients pre- and post-treatment were analyzed by the Wilcoxon test. </plain></SENT>
<SENT sid="277" pm="."><plain>Data are expressed as the means or concentrations for individual subjects who participated in two separate experiments. </plain></SENT>
<SENT sid="278" pm="."><plain>(A) Serum level IL-10 in individual patients’ pre- and post-treatment. </plain></SENT>
<SENT sid="279" pm="."><plain>(B-F) The numbers of CD38+CD19+, CD86+CD19+, IL-10+CD19+, CD5+CD1d+CD19+, and CD5+CD1d+IL-10+CD19+ B cells of individual patients in the pre- and post-treatment stages. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0152368.g005"/></fig></SecTag><SecTag type="FIG"><fig id="pone.0152368.g006" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0152368.g006</object-id><label>Fig 6</label><caption><title><text><SENT sid="280" pm="."><plain>Correlation between the number of CD38+CD19+ B cells and the serum IgA concentration in HSPN patients. </plain></SENT>
</text></title><p><text><SENT sid="281" pm="."><plain>(A) Serum IgA concentrations in HSPN patients and healthy controls. </plain></SENT>
<SENT sid="282" pm="."><plain>Data are expressed as the means or concentrations for individual patients who participated in two separate experiments. </plain></SENT>
<SENT sid="283" pm="."><plain>The horizontal lines indicate the median values for each group. </plain></SENT>
<SENT sid="284" pm="."><plain>(B) The serum IgA concentration was positively correlated with the number of CD38+CD19+ B cells. </plain></SENT>
<SENT sid="285" pm="."><plain>Analyzed by Spearman correlation tests. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0152368.g006"/></fig></SecTag><p><text><SENT sid="286" pm="."><plain>In summary, the treatment dramatically improved proteinuria in patients. </plain></SENT>
<SENT sid="287" pm="."><plain>This finding was accompanied by a reduction in the number of CD38+D19+ B cells. </plain></SENT>
<SENT sid="288" pm="."><plain>However, there were increases in the numbers of IL-10+CD19+, CD1d+CD5+CD19+, and IL-10+CD1d+CD5+CD19+ B cells and the serum IL-10 concentration in HSPN patients following treatment. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="DISCUSS"><sec sec-type="conclusions" id="sec021"><title><text><SENT sid="289" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="290" pm="."><plain>Previous studies have failed to clarify the pathogenesis of HSPN. </plain></SENT>
<SENT sid="291" pm="."><plain>However, they have proved that HSPN is mainly associated with glomerular deposits of an immune complex containing IgA. </plain></SENT>
<SENT sid="292" pm="."><plain>These deposits are primarily found in mesangium. </plain></SENT>
<SENT sid="293" pm="."><plain>Moreover, the deposition of IgA occurs again in some patients who have previously undergone renal transplantation [3]. </plain></SENT>
<SENT sid="294" pm="."><plain>In our study, we have characterized the roles of different subsets of peripheral blood B cells in HSPN patients and HCs. </plain></SENT>
<SENT sid="295" pm="."><plain>In our study, the different B cell subsets were defined as CD38+CD19+, CD86+CD19+, CD38+CD86+CD19+, CD27+CD19+ (activated B cells), CD27-CD19+ (naive B cells), CD95+CD19+, and CD27+CD95+CD19+B cells. </plain></SENT>
<SENT sid="296" pm="."><plain>Thereafter, we analyzed the numbers of these cells per microliter of blood. </plain></SENT>
<SENT sid="297" pm="."><plain>We found that compared to those in HCs, the numbers of CD38+CD19+, CD86+CD19+, CD38+CD86+CD19+, and CD95+CD19+B cells were significantly higher in patients with HSPN. </plain></SENT>
<SENT sid="298" pm="."><plain>However, there were no significant differences in the numbers of CD27+CD19+ and CD27+CD95+CD19+ B cells between the experimental and control groups. </plain></SENT>
<SENT sid="299" pm="."><plain>The high expression of CD86, which activates CD4+ T cells, indicates the activation of B cells [12]. </plain></SENT>
<SENT sid="300" pm="."><plain>Activated B cells can also secrete cytokines and express co-stimulatory molecules, such as CD86 and CD95 [11]. </plain></SENT>
<SENT sid="301" pm="."><plain>Furthermore, it has been proposed that CD95 acts as a key regulator in the activation of germ cell apoptosis [13]. </plain></SENT>
<SENT sid="302" pm="."><plain>This feedback regulation can maintain the homeostasis of B cells in HSPN patients. </plain></SENT>
<SENT sid="303" pm="."><plain>We also analyzed the associations between clinical parameters and the numbers of B cells of different subtypes per microliter of blood. </plain></SENT>
<SENT sid="304" pm="."><plain>We found that 24-h proteinuria is positively correlated with the number of CD38+CD19+ B cells, whereas eGFR is negatively correlated with the number of CD38+CD19+ B cells. </plain></SENT>
<SENT sid="305" pm="."><plain>Furthermore, the numbers of CD38+CD19+ and CD86+CD19+ (activated) B cells were significantly reduced after treatment. </plain></SENT>
<SENT sid="306" pm="."><plain>Consequently, the number of circulating CD86+CD19+ B cells, specifically CD38+CD19+ B cells, may be associated with the pathogenesis of HSPN. </plain></SENT>
</text></p><p><text><SENT sid="307" pm="."><plain>In this experimental study, we also analyzed a new subset of B cells, which are termed Bregs; these cells are characterized by the CD1dhiCD5+CD19+ phenotype [14,29–31]. </plain></SENT>
<SENT sid="308" pm="."><plain>We were surprised to find that compared to those in HCs, the numbers of CD5+CD19+, CD1d+CD19+, IL-10+CD19+, CD1d+CD5+CD19+, and IL-10+CD1d+CD5+CD19+ B cells were significantly lower in HSPN patients. </plain></SENT>
<SENT sid="309" pm="."><plain>Furthermore, 24-h proteinuria was negatively correlated with the serum IL-10 concentration and the numbers of IL-10+CD19+, CD1d+CD5+CD19+, and IL-10+CD1d+CD5+CD19+ B cells. </plain></SENT>
<SENT sid="310" pm="."><plain>In addition, the eGFR was positively correlated with the serum IL-10 concentration and the numbers of IL-10+CD19+, CD1d+CD5+CD19+, and IL-10+CD1d+CD5+CD19+ B cells. </plain></SENT>
<SENT sid="311" pm="."><plain>Interestingly, serum IL-10 levels and the numbers of IL-10+CD19+, CD1d+CD5+CD19+, and IL-10+CD1d+CD5+CD19+ B cells were significantly greater in patients following treatment. </plain></SENT>
<SENT sid="312" pm="."><plain>Based on these results, we speculate that Bregs and the serum IL-10 concentration play pivotal roles in the pathophysiology of HSPN. </plain></SENT>
</text></p><p><text><SENT sid="313" pm="."><plain>Previous studies have also shown that Bregs play a critical role in the regulation of experimental autoimmune encephalomyelitis (EAE) and in the suppression of intestinal inflammation in murine models via IL-10, which has strong anti-inflammatory activity and inhibitory activity on the immune system [23,24]. </plain></SENT>
<SENT sid="314" pm="."><plain>Therefore, we analyzed the correlations between CD19+ B cell subtypes and the IL-10–producing B cells. </plain></SENT>
<SENT sid="315" pm="."><plain>We have found that the number of CD38+CD19+B cells was negatively correlated with the serum IL-10 concentration and the number of IL-10+CD19+ B cells per microliter of blood. </plain></SENT>
<SENT sid="316" pm="."><plain>Conversely, the numbers of CD1d+CD5+CD19+and IL-10+CD1d+CD5+CD19+ B cells per microliter of blood were positively correlated with the serum IL-10 concentration. </plain></SENT>
<SENT sid="317" pm="."><plain>These results support the above assumptions, which indicate that a decrease in the number of Bregs can in turn reduce the serum level of IL-10. </plain></SENT>
<SENT sid="318" pm="."><plain>Consequently, there is a reduction in the immunosuppressive effect, leading to a high number of CD38+CD19+ B cells in patients with HSPN. </plain></SENT>
<SENT sid="319" pm="."><plain>An enhanced immune response may stimulate the expression of antigen, and as a result, the deposition of antibody immune complex may be favored in the mesangium, promoting the pathogenesis of HSPN. </plain></SENT>
</text></p><p><text><SENT sid="320" pm="."><plain>In conclusion, our data indicate that CD38+CD19+ B cells and Bregs may participate in the pathogenesis of HSPN. </plain></SENT>
<SENT sid="321" pm="."><plain>Because HSPN is mainly associated with glomerular deposits of an immune complex containing IgA, we also analyzed the serum level of IgA in patients with HSPN and found that the serum IgA concentration was positively correlated with the number of CD38+CD19+ B cells. </plain></SENT>
<SENT sid="322" pm="."><plain>In addition, a previous study has indicated that 24-h urinary protein can predict the pathological classification of HSPN [37]. </plain></SENT>
<SENT sid="323" pm="."><plain>Given that HSPN is a serious pathological condition arising from Henoch—Schoenlein purpura, we analyzed the numbers of neutrophils from the patients with HSPN to explore whether our findings represent only a general inflammatory response. </plain></SENT>
<SENT sid="324" pm="."><plain>We found that the number of Bregs has no correlation with the number of neutrophils (data not shown), suggesting that our findings do not represent a general inflammatory response. </plain></SENT>
<SENT sid="325" pm="."><plain>Although previous studies have shown that the levels of CD5+ B cells and IL-10+ B cells are decreased in antineutrophil cytoplasmic antibody-associated vasculitis [38–41] and the frequency of IL-10–producing B cells is higher in hepatitis B virus-associated membranous nephropathy [42], our study is the first to indicate that CD38+CD19+ B cells and Bregs may participate in the pathogenesis of HSPN. </plain></SENT>
</text></p><p><text><SENT sid="326" pm="."><plain>Our findings suggest that CD38+CD19+ B cells and Bregs may contribute to the pathogenesis of HSPN, and we also propose that CD38+CD19+ B cells and Bregs can serve as biomarkers in the evaluation of the severity of disease. </plain></SENT>
<SENT sid="327" pm="."><plain>However, our research design has some limitations, including the very small sample size. </plain></SENT>
<SENT sid="328" pm="."><plain>Moreover, a longitudinal follow-up was not observed among the included subjects and we did not carry out any single time-point measurements. </plain></SENT>
<SENT sid="329" pm="."><plain>Furthermore, our findings regarding CD38+ B cells could result from correlations with either transitional B cells or plasma blasts [43]. </plain></SENT>
<SENT sid="330" pm="."><plain>Also, the CD27-CD19+ B cells are a mixture of IgM+ naive B cells and IgM-IgD- memory B cells (IgA, IgG, or IgE) [44,45]. </plain></SENT>
<SENT sid="331" pm="."><plain>Thus, further dissection of the actual association with either of these subsets is needed. </plain></SENT>
<SENT sid="332" pm="."><plain>Nonetheless, our data provide novel insights into the unknown pathophysiology and mechanisms of HSPN. </plain></SENT>
<SENT sid="333" pm="."><plain>Further studies should be conducted to explore the roles of different subsets of B cells in the pathogenesis of HSPN and to gain an understanding of the mechanisms of regulation and activation of Bregs. </plain></SENT>
<SENT sid="334" pm="."><plain>Such studies are likely to identify a new target that can be used for medical intervention in HSPN patients. </plain></SENT>
</text></p></sec></SecTag><SecTag type="SUPPL"><sec sec-type="supplementary-material" id="sec022"><title><text><SENT sid="335" pm="."><plain>Supporting Information </plain></SENT>
</text></title><supplementary-material content-type="local-data" id="pone.0152368.s001"><label>S1 Fig</label><caption><title><text><SENT sid="336" pm="."><plain>The raw data of Bregs in 25 HSPN patients. </plain></SENT>
</text></title><p><text><SENT sid="337" pm="."><plain>(ZIP) </plain></SENT>
</text></p></caption><media xlink:href="pone.0152368.s001.zip"><caption><p><text><SENT sid="338" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0152368.s002"><label>S1 Table</label><caption><title><text><SENT sid="339" pm="."><plain>Details of antibodies used for flow cytometry. </plain></SENT>
</text></title><p><text><SENT sid="340" pm="."><plain>(ZIP) </plain></SENT>
</text></p></caption><media xlink:href="pone.0152368.s002.zip"><caption><p><text><SENT sid="341" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0152368.s003"><label>S2 Table</label><caption><title><text><SENT sid="342" pm="."><plain>Clinical and basic immunological parameters. </plain></SENT>
</text></title><p><text><SENT sid="343" pm="."><plain>(ZIP) </plain></SENT>
</text></p></caption><media xlink:href="pone.0152368.s003.zip"><caption><p><text><SENT sid="344" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material></sec></SecTag></body><back><SecTag type="REF"><ref-list><title>References</title><ref id="pone.0152368.ref001"><text><SENT sid="345" pm="."><plain>1PilleboutE, VerineJ. Henoch-Schonlein purpura in the adult. Rev Med Interne 2014; 35(6):372–81. 10.1016/j.revmed.2013.12.004 <?supplied-pmid 24657040?>24657040 </plain></SENT>
</text></ref><ref id="pone.0152368.ref002"><text><SENT sid="346" pm="."><plain>2KangY, ParkJS, HaYJ, KangMI, ParkHJ, LeeSW, et al Differences in clinical manifestations and outcomes between adult and child patients with Henoch-Schonlein purpura. J Korean Med Sci 2014; 29(2):198–203. 10.3346/jkms.2014.29.2.198 <?supplied-pmid 24550645?>24550645 </plain></SENT>
</text></ref><ref id="pone.0152368.ref003"><text><SENT sid="347" pm="."><plain>3PohlM. Henoch-Schonlein purpura nephritis. Pediatr Nephrol 2015; 30(2):245–52. 10.1007/s00467-014-2815-6 <?supplied-pmid 24733586?>24733586 </plain></SENT>
</text></ref><ref id="pone.0152368.ref004"><text><SENT sid="348" pm="."><plain>4MoroniG, GallelliB, DianaA, CarminatiA, BanfiG, PoliF, et al Renal transplantation in adults with Henoch-Schonlein purpura: long-term outcome. Nephrol Dial Transplant 2008; 23:3010–3016. 10.1093/ndt/gfn209 <?supplied-pmid 18424819?>18424819 </plain></SENT>
</text></ref><ref id="pone.0152368.ref005"><text><SENT sid="349" pm="."><plain>5SolerMJ, MirM, RodriguezE, OrfilaA, MunneA, VazquezS, et al Recurrence of IgA nephropathy and Henoch-Schonlein purpura after kidney transplantation: risk factors and graft survival. Transplant Proc 2005; 37:3705–3709. <?supplied-pmid 16386512?>16386512 </plain></SENT>
</text></ref><ref id="pone.0152368.ref006"><text><SENT sid="350" pm="."><plain>6JiS, LiuM, ChenJ, YinL, ShaG, ChenH, et al The fate of glomerular mesangial IgA deposition in the donated kidney after allograft transplantation. Clin Transplant 2004; 18:536–540. <?supplied-pmid 15344956?>15344956 </plain></SENT>
</text></ref><ref id="pone.0152368.ref007"><text><SENT sid="351" pm="."><plain>7SanterDM, MaMM, HockmanD, LandiA, TyrrellDL, HoughtonM. Enhanced Activation of Memory, but Not Naive, B Cells in Chronic Hepatitis C Virus-Infected Patients with Cryoglobulinemia and Advanced Liver Fibrosis. PLoS One 2013; 8:e68308 10.1371/journal.pone.0068308 <?supplied-pmid 23840845?>23840845 </plain></SENT>
</text></ref><ref id="pone.0152368.ref008"><text><SENT sid="352" pm="."><plain>8KleinU, RajewskyK, KuppersRU. Human immunoglobu-€ lin (Ig)M+IgD+ peripheral blood B-cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B-cells. J Exp Med 1998; 188:1679–89. <?supplied-pmid 9802980?>9802980 </plain></SENT>
</text></ref><ref id="pone.0152368.ref009"><text><SENT sid="353" pm="."><plain>9PeiselerM, SebodeM, FrankeB, WortmannF, SchwingeD, QuaasA, et al FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency. J Hepatol 2012; 57: 125–32. 10.1016/j.jhep.2012.02.029 <?supplied-pmid 22425700?>22425700 </plain></SENT>
</text></ref><ref id="pone.0152368.ref010"><text><SENT sid="354" pm="."><plain>10ZhongX, TumangJR, GaoW, BaiC, RothsteinTL. PD-L2 expression extends beyond dendritic cells/macrophages to B1 cells enriched for V(H)11/V(H)12 and phosphatidyl choline binding. Eur J Immunol 2007; 37: 2405–10. <?supplied-pmid 17683117?>17683117 </plain></SENT>
</text></ref><ref id="pone.0152368.ref011"><text><SENT sid="355" pm="."><plain>11ArpinC, DéchanetJ, Van KootenC, MervilleP, GrouardG, BrièreF, et al Generation of memory B-cells and plasma cells in vitro. Science 1995; 268: 720–2. <?supplied-pmid 7537388?>7537388 </plain></SENT>
</text></ref><ref id="pone.0152368.ref012"><text><SENT sid="356" pm="."><plain>12MenezesSM, DecanineD, BrassatD, KhouriR, SchnitmanSV, KruschewskyR, et al CD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis. J Neuroinflammation. 2014 1 29;11:18 10.1186/1742-2094-11-18 <?supplied-pmid 24472094?>24472094 </plain></SENT>
</text></ref><ref id="pone.0152368.ref013"><text><SENT sid="357" pm="."><plain>13QiS, FuW, WangC, LiuC, QuanC, KouroumaA, et al BPA-induced apoptosis of rat Sertoli cells through Fas/FasL and JNKs/p38 MAPK pathways. J Reproductive Toxicology 2014; 50: 108–116. </plain></SENT>
</text></ref><ref id="pone.0152368.ref014"><text><SENT sid="358" pm="."><plain>14MizoguchiA, BhanA. A case for regulatory B cells. Immunol 2006; 176:705–710. </plain></SENT>
</text></ref><ref id="pone.0152368.ref015"><text><SENT sid="359" pm="."><plain>15FremdC, SchuetzF, SohnC, BeckhoveP, DomschkeC. B cell-regulated immune responses in tumor models and cancer patients. Oncoimmunology 2013; 2: e25443 <?supplied-pmid 24073382?>24073382 </plain></SENT>
</text></ref><ref id="pone.0152368.ref016"><text><SENT sid="360" pm="."><plain>16GundersonAJ, CoussensLM. B cells and their mediators as targets for therapy in solid tumors. Exp Cell Res 2013; 319: 1644–1649. 10.1016/j.yexcr.2013.03.005 <?supplied-pmid 23499742?>23499742 </plain></SENT>
</text></ref><ref id="pone.0152368.ref017"><text><SENT sid="361" pm="."><plain>17NelsonBH. CD20+B cells: the other tumor-infiltrating lymphocytes. J Immunol 2010; 185(9):4977–4982. 10.4049/jimmunol.1001323 <?supplied-pmid 20962266?>20962266 </plain></SENT>
</text></ref><ref id="pone.0152368.ref018"><text><SENT sid="362" pm="."><plain>18de VisserKE, KoretsLV, CoussensLM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005; 7(5): 411–423. <?supplied-pmid 15894262?>15894262 </plain></SENT>
</text></ref><ref id="pone.0152368.ref019"><text><SENT sid="363" pm="."><plain>19SchioppaT, MooreR, ThompsonRG, RosserEC, KulbeH, NedospasovS, et al B regulatory cells and the tumor-promoting actions of TNFalpha during squamous carcinogenesis. Proc Natl Acad Sci USA 2011; 108: 10662–10667. 10.1073/pnas.1100994108 <?supplied-pmid 21670304?>21670304 </plain></SENT>
</text></ref><ref id="pone.0152368.ref020"><text><SENT sid="364" pm="."><plain>20NzulaS, GoingJJ, StottDI. Antigen-driven clonal proliferation, somatic hypermutation,and selection of B lymphocytes infiltrating human ductal breast carcinomas. Cancer Res 2003; 63:3275–3280. <?supplied-pmid 12810659?>12810659 </plain></SENT>
</text></ref><ref id="pone.0152368.ref021"><text><SENT sid="365" pm="."><plain>21KammertoensT, QinZ, BriesemeisterD, BendelacA, BlankensteinT. B-cells and IL-4 promote methylcholanthrene-induced carcinogenesis but there is no evidence for a role of T/NKT-cells and their effector molecules (Fas-ligand, TNF-alpha, perforin). Int J Cancer 2012; 131:1499–1508. 10.1002/ijc.27411 <?supplied-pmid 22212899?>22212899 </plain></SENT>
</text></ref><ref id="pone.0152368.ref022"><text><SENT sid="366" pm="."><plain>22AmmiranteM, LuoJL, GrivennikovS, NedospasovS, KarinM. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 2010; 464: 302–305. 10.1038/nature08782 <?supplied-pmid 20220849?>20220849 </plain></SENT>
</text></ref><ref id="pone.0152368.ref023"><text><SENT sid="367" pm="."><plain>23MizoguchiA, MizoguchiE, TakedatsuH, BlumbergRS, BhanAK. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 2002; 16: 219–230. <?supplied-pmid 11869683?>11869683 </plain></SENT>
</text></ref><ref id="pone.0152368.ref024"><text><SENT sid="368" pm="."><plain>24FillatreauS, SweenieCH, McGeachyMJ, GrayD, AndertonSM. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002; 3: 944–950. <?supplied-pmid 12244307?>12244307 </plain></SENT>
</text></ref><ref id="pone.0152368.ref025"><text><SENT sid="369" pm="."><plain>25ZhangN, ZhaoP, ShresthaA, ZhangL, QuZ, LiuM, et al A higher frequency of CD4⁺CXCR5⁺ T follicular helper cells in adult patients with minimal change disease. Biomed Res Int 2014; 836157 10.1155/2014/836157 <?supplied-pmid 25243187?>25243187 </plain></SENT>
</text></ref><ref id="pone.0152368.ref026"><text><SENT sid="370" pm="."><plain>26LiuY, ZhaoP, QuZ, AyanaDA, JiangY. Frequency of CD4+CXCR5+ TFH cells in patients with hepatitis b virus-associated membranous nephropathy. Int Immunopharmacol. 2014 9; 22(1):98–106. 10.1016/j.intimp.2014.06.024 <?supplied-pmid 24975830?>24975830 </plain></SENT>
</text></ref><ref id="pone.0152368.ref027"><text><SENT sid="371" pm="."><plain>27WangYY, ZhangL, ZhaoPW, MaL, LiC, ZouHB, et al Functional implications of regulatory B cells in human IgA nephropathy. Scand J Immunol. 2014 1; 79(1):51–60. 10.1111/sji.12128 <?supplied-pmid 24219615?>24219615 </plain></SENT>
</text></ref><ref id="pone.0152368.ref028"><text><SENT sid="372" pm="."><plain>28CarterNA, RosserEC, MauriC. Interleukin-10 produced by B cells is crucial for the suppression of Th17/Th1 responses, induction of T regulatory type 1 cells and reduction of collagen-induced arthritis. Arthritis Res Ther 2012; 14: R32 10.1186/ar3736 <?supplied-pmid 22315945?>22315945 </plain></SENT>
</text></ref><ref id="pone.0152368.ref029"><text><SENT sid="373" pm="."><plain>29YanabaK, BouazizJD, HaasKM, PoeJC, FujimotoM, TedderTF. A regulatory B cell subset with a unique CD1dhiCD5+phenotype controls T cell-dependent in flammatory responses. Immunity, 2008; 28:639–50. 10.1016/j.immuni.2008.03.017 <?supplied-pmid 18482568?>18482568 </plain></SENT>
</text></ref><ref id="pone.0152368.ref030"><text><SENT sid="374" pm="."><plain>30van der VlugtLE, LabudaLA, Ozir-FazalalikhanA, LieversE, GloudemansAK, LiuKY, et al Schistosomes induce regulatory features in human and mouse CD1d(hi) B cells: inhibition of allergic inflammation by IL-10 and regulatory T cells. PLoS One 2012; 7: e30883 10.1371/journal.pone.0030883 <?supplied-pmid 22347409?>22347409 </plain></SENT>
</text></ref><ref id="pone.0152368.ref031"><text><SENT sid="375" pm="."><plain>31SunF, LadhaSS, YangL, LiuQ, ShiSX, SuN, et al Interleukin-10 producing B cells and their association with responsiveness to rituximab in myasthenia gravis. Muscle Nerve, 2014; 49:487–94. 10.1002/mus.23951 <?supplied-pmid 23868194?>23868194 </plain></SENT>
</text></ref><ref id="pone.0152368.ref032"><text><SENT sid="376" pm="."><plain>32OzenS, PistorioA, IusanSM, BakkalogluA, HerlinT, BrikR, et al EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008: part II: final classification criteria. Ann Rheum Dis 2010; 69:798–806. 10.1136/ard.2009.116657 <?supplied-pmid 20413568?>20413568 </plain></SENT>
</text></ref><ref id="pone.0152368.ref033"><text><SENT sid="377" pm="."><plain>33NarchiH. Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child 2005; 90:916–920. <?supplied-pmid 15871983?>15871983 </plain></SENT>
</text></ref><ref id="pone.0152368.ref034"><text><SENT sid="378" pm="."><plain>34RonkainenJ, Ala-HouhalaM, HuttunenNP, JahnukainenT, KoskimiesO, OrmalaT, et al Outcome of Henoch-Schoenlein nephritis with nephrotic-range proteinuria. Clin Nephrol 2003; 60:80–84. <?supplied-pmid 12940608?>12940608 </plain></SENT>
</text></ref><ref id="pone.0152368.ref035"><text><SENT sid="379" pm="."><plain>35FlorkowskiCM, Chew-HarrisJS. Methods of estimating GFR-different equations including CKD-EPI. Clin Biochem Rev 2011; 32:75–79. <?supplied-pmid 21611080?>21611080 </plain></SENT>
</text></ref><ref id="pone.0152368.ref036"><text><SENT sid="380" pm="."><plain>36JiangY, MaZ, XinG, YanH, LiW, XuH, et al Th1 and Th2 immune response in chronic hepatitis B patients during a long-term treatment with adefovir dipivoxil. Mediators Inflamm 2010; 143026. </plain></SENT>
</text></ref><ref id="pone.0152368.ref037"><text><SENT sid="381" pm="."><plain>37YeQ, ShangSQ, LiuAM, ZhangT, ShenHQ, ChenXJ, et al 24h Urinary Protein Levels and Urine Protein/Creatinine Ratios Could Probably Forecast the Pathological Classification of HSPN. PLoS One 2015; 10(5):e0127767 10.1371/journal.pone.0127767 <?supplied-pmid 25996387?>25996387 </plain></SENT>
</text></ref><ref id="pone.0152368.ref038"><text><SENT sid="382" pm="."><plain>38AybarLT, McGregorJG, HoganSL, HuY, MendozaCE, BrantEJ, et al Reduced CD5(+) CD24(hi) CD38(hi) and interleukin-10(+) regulatory B cells in active anti-neutrophil cytoplasmic autoantibody-associated vasculitis permit increased circulating autoantibodies. Clin Exp Immunol 2015; 180(2):178–88. 10.1111/cei.12483 <?supplied-pmid 25376552?>25376552 </plain></SENT>
</text></ref><ref id="pone.0152368.ref039"><text><SENT sid="383" pm="."><plain>39DumoitierN, TerrierB, LondonJ, LofekS, MouthonL. Implication of B lymphocytes in the pathogenesis of ANCA-associated vasculitides. Autoimmun Rev 2015; 14(11):996–1004. 10.1016/j.autrev.2015.06.008 <?supplied-pmid 26143354?>26143354 </plain></SENT>
</text></ref><ref id="pone.0152368.ref040"><text><SENT sid="384" pm="."><plain>40JennetteJC, FalkRJ. B cell-mediated pathogenesis of ANCA-mediated vasculitis. Semin Immunopathol 2014; 36(3):327–38. 10.1007/s00281-014-0431-y <?supplied-pmid 24777746?>24777746 </plain></SENT>
</text></ref><ref id="pone.0152368.ref041"><text><SENT sid="385" pm="."><plain>41UnizonyS, LimN, PhippardDJ, CareyVJ, MiloslavskyEM, TchaoNK, et al Peripheral CD5+ B cells in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol 2015; 67(2):535–44. 10.1002/art.38916 <?supplied-pmid 25332071?>25332071 </plain></SENT>
</text></ref><ref id="pone.0152368.ref042"><text><SENT sid="386" pm="."><plain>42LiuY, WangH, HuX, QuZ, ZhangH, CrewR, et al A higher frequency of IL-10-producing B cells in Hepatitis B virus associated membranous nephropathy. Clin Exp Pharmacol Physiol 2016 1 30. </plain></SENT>
</text></ref><ref id="pone.0152368.ref043"><text><SENT sid="387" pm="."><plain>43SimsGP, EttingerR, ShirotaY, YarboroCH, IlleiGG, LipskyPE. Identification and characterization of circulating human transitional B cells. Blood 2005; 105(11):4390–8. <?supplied-pmid 15701725?>15701725 </plain></SENT>
</text></ref><ref id="pone.0152368.ref044"><text><SENT sid="388" pm="."><plain>44BerkowskaMA, DriessenGJ, BikosV, Grosserichter-WagenerC, StamatopoulosK, CeruttiA, et al Human memory B cells originate from three distinct germinal center-dependent and -independent maturation pathways. Blood 2011; 118(8):2150–8. 10.1182/blood-2011-04-345579 <?supplied-pmid 21690558?>21690558 </plain></SENT>
</text></ref><ref id="pone.0152368.ref045"><text><SENT sid="389" pm="."><plain>45BerkowskaMA, HeeringaJJ, HajdarbegovicE, van der BurgM, ThioHB, van HagenPM, et al Human IgE(+) B cells are derived from T cell-dependent and T cell-independent pathways. J Allergy Clin Immunol 2014; 134(3):688–697. 10.1016/j.jaci.2014.03.036 <?supplied-pmid 24835500?>24835500 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
